{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:27:38Z","timestamp":1792704458217,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-68411-w","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T16:04:41Z","timestamp":1722441881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Heterogeneity of claudin 18.2 expression in metastatic gastric cancer"],"prefix":"10.1038","volume":"14","author":[{"given":"Eugene","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinho","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hee","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Don","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"68411_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"68411_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376, 687\u2013697 (2010).","journal-title":"Lancet"},{"key":"68411_CR3","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara, K. et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N. Engl. J. Med. 382, 2419\u20132430 (2020).","journal-title":"N. Engl. J. Med."},{"key":"68411_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet 398, 27\u201340 (2021).","journal-title":"Lancet"},{"key":"68411_CR5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha, S. Y. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): A multicentre, randomised, double-blind, phase 3 trial. The Lancet Oncol. 24, 1181\u20131195 (2023).","journal-title":"The Lancet Oncol."},{"key":"68411_CR6","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin, U. et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin. Cancer Res. 14, 7624\u20137634 (2008).","journal-title":"Clin. Cancer Res."},{"key":"68411_CR7","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara, K. et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial. Lancet 401, 1655\u20131668 (2023).","journal-title":"Lancet"},{"key":"68411_CR8","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah, M. A. et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: The randomized, phase 3 GLOW trial. Nat. Med. 29, 2133\u20132141 (2023).","journal-title":"Nat. Med."},{"key":"68411_CR9","volume-title":"A Phase 1a Dose-Escalation, Multicenter Trial of Anti-claudin 18.2 Antibody Drug Conjugate CMG901 in Patients with Resistant\/Refractory Solid Tumors","author":"R-H Xu","year":"2023","unstructured":"Xu, R.-H. et al. A Phase 1a Dose-Escalation, Multicenter Trial of Anti-claudin 18.2 Antibody Drug Conjugate CMG901 in Patients with Resistant\/Refractory Solid Tumors (American Society of Clinical Oncology, 2023)."},{"key":"68411_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41571-021-00492-2","volume":"18","author":"Y Nakamura","year":"2021","unstructured":"Nakamura, Y., Kawazoe, A., Lordick, F., Janjigian, Y. Y. & Shitara, K. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: An emerging paradigm. Nat. Rev. Clin. Oncol. 18, 473\u2013487 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"68411_CR11","first-page":"1","volume":"1","author":"C Valenza","year":"2023","unstructured":"Valenza, C. et al. Targeting HER2 heterogeneity in breast and gastrointestinal cancers. Trends Cancer 1, 1 (2023).","journal-title":"Trends Cancer"},{"key":"68411_CR12","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s10120-022-01298-6","volume":"25","author":"K Bang","year":"2022","unstructured":"Bang, K. et al. Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab. Gastric Cancer 25, 794\u2013803 (2022).","journal-title":"Gastric Cancer"},{"key":"68411_CR13","doi-asserted-by":"publisher","first-page":"100762","DOI":"10.1016\/j.esmoop.2022.100762","volume":"8","author":"Y Kubota","year":"2023","unstructured":"Kubota, Y. et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open 8, 100762 (2023).","journal-title":"ESMO Open"},{"key":"68411_CR14","doi-asserted-by":"publisher","first-page":"20047","DOI":"10.1038\/s41598-023-47178-6","volume":"13","author":"HD Kim","year":"2023","unstructured":"Kim, H. D. et al. Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer. Sci. Rep. 13, 20047 (2023).","journal-title":"Sci. Rep."},{"key":"68411_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41416-019-0508-4","volume":"121","author":"I Coati","year":"2019","unstructured":"Coati, I. et al. Claudin-18 expression in oesophagogastric adenocarcinomas: A tissue microarray study of 523 molecularly profiled cases. Br. J. Cancer 121, 257\u2013263 (2019).","journal-title":"Br. J. Cancer"},{"key":"68411_CR16","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00428-019-02624-7","volume":"475","author":"M Dottermusch","year":"2019","unstructured":"Dottermusch, M., Kr\u00fcger, S., Behrens, H. M., Halske, C. & R\u00f6cken, C. Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: Results from a large Caucasian cohort study. Virchows Arch. 475, 563\u2013571 (2019).","journal-title":"Virchows Arch."},{"key":"68411_CR17","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/jjco\/hyz068","volume":"49","author":"C Rohde","year":"2019","unstructured":"Rohde, C. et al. Comparison of claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. Jpn. J. Clin. Oncol. 49, 870\u2013876 (2019).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"68411_CR18","doi-asserted-by":"publisher","first-page":"6453","DOI":"10.1158\/1078-0432.CCR-20-2085","volume":"26","author":"KI Zhou","year":"2020","unstructured":"Zhou, K. I. et al. Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. Clin. Cancer Res. 26, 6453\u20136463 (2020).","journal-title":"Clin. Cancer Res."},{"key":"68411_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.4251\/wjgo.v15.i2.343","volume":"15","author":"E Kayikcioglu","year":"2023","unstructured":"Kayikcioglu, E., Y\u00fcceer, R. O., Cetin, B., Y\u00fcceer, K. & Karahan, N. Prognostic value of claudin 18.2 expression in gastric adenocarcinoma. World J. Gastrointest. Oncol. 15, 343\u2013351 (2023).","journal-title":"World J. Gastrointest. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68411-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68411-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68411-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T16:27:47Z","timestamp":1722443267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68411-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["68411"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-68411-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"assertion":[{"value":"15 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M-H.R. received honoraria from DAEHWA Pharmaceutical, Bristol Myers Squibb, Lilly, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Novartis, Daiichi Sankyo and AstraZeneca, and served as a consultant for DAEHWA Pharmaceutical, Bristol Myers Squibb, Lilly and Ono Pharmaceutical. H-D.K. received honoraria from AstraZeneca, Bristol Myers Squibb, Ono Pharmaceuticals, Boryung Pharmaceuticals, and Boostimmune; and served as a consultant for Mustbio. E.C., J.S, and Y.S.P. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17648"}}